Loading stock data…
uniQure N.V (QURE)
$47.39-0.12 (-0.25%)
After Hours$47.49+0.10 (+0.21%)· Last close Jun 29
uniQure N.V.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
uniQure N.V. in the Healthcare sector is trading at $47.39 with a market capitalization of $1.7B. Wall Street consensus targets $64.66 (11 analysts), implying a +36.4% move over the next 12 months. The stock is currently 34% below its 52-week high of $71.50, remaining 66.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.56M↓ | $5.57M↑ | $3.70M↓ | $5.26M↑ | $1.57M |
| Gross Profit | $3.34M↓ | $5.13M↑ | $3.30M↓ | $4.61M↑ | $1.37M |
| Operating Income | -$44.27M↑ | -$51.49M↓ | -$49.49M↓ | -$42.88M↓ | -$37.37M |
| Net Income | -$53.53M↓ | -$37.09M↑ | -$80.53M↓ | -$37.72M↑ | -$43.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.86%
Volume
Today's trading volume
2.28M
Recent News
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. UniQure N.V. (NASDAQ:QURE) is among the best healthcare stocks. TheFly reported on June 18 that Barclays raised its rating on QURE to Overweight from Equal Weight and increased its price target to $65 from $25. The firm viewed […]
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight. Read that last number again. This stock nearly doubled in a single session. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, I could just tell you “wow, what a move” and carry on with my day. But that’s not what I do, and it’s not wh
uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk
uniQure is back in focus after modelled fair value estimates shifted from about US$39.05 to roughly US$52.56, a change that has fed directly into higher price targets across some recent research. Analysts linking this move to the evolving AMT-130 story in Huntington’s disease point to the planned biologics license application and earlier regulatory feedback as key inputs into how they now frame risk and potential reward, even as others stay cautious. Read on to see what is driving these...